Olcegepant
Cat. No.：YN320092
CAS No. ：204697-65-4
| 产品名称: | Olcegepant |
| CAS No.: | 204697-65-4 |
| Chemical Name: | 1-[3,5-Dibromo-N-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]-D-tyrosyl-L-lysyl]-4-(4-pyridinyl)piperazine; N-[(1R)-2-[[(1S)-5-Amino-1-[[4-(4-pyridinyl)-1-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-o |
| Synonyms: | BIBN-4096; BIBN 4096BS |
| 分子量: | 869.65 |
| 分子式: | C₃₈H₄₇Br₂N₉O₅ |
| SMILES: | O=C1N(CC2=C(N1)C=CC=C2)C3CCN(C(N[C@@H](C(N[C@H](C(N4CCN(C5=CC=NC=C5)CC4)=O)CCCCN)=O)CC6=CC(Br)=C(C(Br)=C6)O)=O)CC3 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Olcegepant (BIBN-4096) 是有效和选择性的降钙素基因相关肽1 (CGRP1) 受体拮抗剂，IC50和Ki分别为0.03 nM，14.4 pM。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Negro, A. et al.: Exp. Opin. Invest. Drugs, 21, 807 (2012)
Dood, H. et al.: Br. J. Pharmacol., 129, 420 (2000)
Rudol, K. et al.: J. Med. Chem., 48, 5921 (2005)
